https://www.selleckchem.com/pr....oducts/Cediranib.htm
In the present study, the EDP-M regimen is confirmed to have a limited efficacy. Early disease progression does not mean treatment inefficacy. Surgery of residual disease in partially responding patients allows for the detection of pCR in few of them and this condition is predictive of long-term survival. Ki67 expression of post-chemotherapy residual disease could be an additional prognostic factor that deserves to be studied further.The purpose of this study was to investigate the effect of continuous case management with a flexible
إعجاب
علق
شارك
